Published in Blood Weekly, December 20th, 2001
TAXUS I was designed to assess the safety of a slow-release dose formulation, paclitaxel-eluting coronary stent for the treatment of restenosis. The new data bolster previously reported interim results of zero restenosis and zero thrombosis for the TAXUS I trial, announced on September 24, 2001.
Boston Scientific also provided updates on the progress of the TAXUS II and TAXUS III trials, as well as the status of its submission to the U.S. Food and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.